Systemic complement profiling in multiple sclerosis as a biomarker of disease state.
Systemic complement profiling in multiple sclerosis as a biomarker of disease state.
复制标题
DOI：
10.1177/1352458512438238
复制
发表时间：
2012-10
期刊：
影响因子：
--
通讯作者：
Morgan BP
中科院分区：
文献类型：
--
作者：
Ingram G;Hakobyan S;Hirst CL;Harris CL;Loveless S;Mitchell JP;Pickersgill TP;Robertson NP;Morgan BP
越来越多的证据表明，补体在多发性硬化症（MS）中存在显著的、动态的全身激活和上调，这可能与疾病的发病机制有关。我们的目的是研究补体在多发性硬化症中的病理作用，以及补体谱作为多发性硬化症疾病状态的生物标志物的潜在作用。在不同临床阶段的多发性硬化症患者和匹配对照组的血浆和脑脊液（CSF）中测量了补体经典、替代和终点途径的关键成分。与对照组相比，MS患者血浆中C3 （p<0.003）、C4 （p<0.001）、C4a （p<0.001）、C1抑制剂（p<0.001）和因子H （p<0.001）水平升高，C9水平降低（p<0.001）。这些分析的综合分析产生了一个统计模型，当结合选定的人口统计数据时，MS的预测值为97%，临床复发的预测值为73%。csf -血浆相关性表明这些成分的合成来源既有系统性的，也有中枢性的。这些数据进一步证明了补体在多发性硬化症中局部和全身表达和激活的改变，并表明补体谱分析可能作为多发性硬化症的生物标志物提供了信息，尽管需要进一步的工作来确定其在区分多发性硬化症中的用途。
There is increasing evidence of significant and dynamic systemic activation and upregulation of complement in multiple sclerosis (MS), which may contribute to disease pathogenesis. We aimed to investigate the pathological role of complement in MS and the potential role for complement profiling as a biomarker of MS disease state. Key components of the classical, alternative and terminal pathways of complement were measured in plasma and cerebrospinal fluid (CSF) of patients with MS in different clinical phases of disease and in matched controls. Increased plasma levels of C3 (p<0.003), C4 (p<0.001), C4a (p<0.001), C1 inhibitor (p<0.001), and factor H (p<0.001), and reduced levels of C9 (p<0.001) were observed in MS patients compared with controls. Combined profiling of these analytes produced a statistical model with a predictive value of 97% for MS and 73% for clinical relapse when combined with selected demographic data. CSF-plasma correlations suggested that source of synthesis of these components was both systemic and central. These data provide further evidence of alterations in both local and systemic expression and activation of complement in MS and suggest that complement profiling may be informative as a biomarker of MS disease, although further work is needed to determine its use in distinguishing MS from its differential.
登录
查看更多内容
影响因子：
11.2
作者：
McDonald, WI;Compston, A;Wolinsky, JS
通讯作者：
Wolinsky, JS
影响因子：
2.9
作者：
LUMSDEN, CE
通讯作者：
LUMSDEN, CE
影响因子：
2.8
作者：
Hutchinson, Michael
通讯作者：
Hutchinson, Michael
影响因子：
168.9
作者：
MORGAN, BP;CAMPBELL, AK;COMPSTON, DAS
通讯作者：
COMPSTON, DAS
影响因子：
3.3
作者：
PIDDLESDEN, SJ;MORGAN, BP
通讯作者：
MORGAN, BP